3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Smoking Cessation
1
Melanoma
1
Gastrointestinal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
44
Cyclophosphamide
21
Nivolumab
18
fludarabine
10
durvalumab
8
Paclitaxel
8
Magnetic Resonance Spectroscopy
8
Interleukin-2
8
Docetaxel
8
aldesleukin
7
Radiosurgery
7
Ipilimumab
7
spartalizumab
6
poly ICLC
6
fludarabine phosphate
6
atezolizumab
6
Specimen Handling
6
Radiotherapy
6
Carboplatin
6
cemiplimab
5
Drug Therapy
5
Cisplatin
5
Biopsy
5
Temozolomide
4
Immune Checkpoint Inhibitors
4
tremelimumab
3
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
3
pazopanib
3
avelumab
3
Trastuzumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Nicotine Replacement Therapy
×
Breast
×
Clear all
NCT04899492
2024-11-07
RESPIRE
Institut Cancerologie de l'Ouest
Phase NA
Terminated
22 enrolled